Hudson Executive Capital Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CATM
Cardtronics plc Class A Ordinary Shares (UK)
CATM
|
+$38.9M |
| 2 |
ACOR
Acorda Therapeutics
ACOR
|
+$10M |
| 3 |
AtriCure
ATRC
|
+$2.98M |
| 4 |
FCB
FCB Financial Holdings, Inc.
FCB
|
+$2.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CIT
CIT Group Inc.
CIT
|
+$10.6M |
| 2 |
MGLN
Magellan Health Services, Inc.
MGLN
|
+$8.52M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.52% |
| 2 | Financials | 21.18% |
| 3 | Industrials | 17.3% |
Similar funds
Hudson Executive Capital's Q4 2017 Portfolio in Review
As of Q4 2017, Hudson Executive Capital held 8 positions worth $208M, up 4.8% from $199M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Hudson Executive Capital deployed $34.9M of net new capital in Q4 2017, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Cardtronics plc Class A Ordinary Shares (UK): 1,945,655 shares worth $36M.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 74% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was CIT Group Inc., an estimated $10.6M trimmed.
- Hudson Executive Capital's largest Q4 2017 buy was Cardtronics plc Class A Ordinary Shares (UK): 1,945,655 shares worth $36M.
- Hudson Executive Capital added most to Acorda Therapeutics in Q4 2017, an estimated $10M increase.
- Hudson Executive Capital's biggest Q4 2017 reduction was CIT Group Inc., cutting an estimated $10.6M.
- Hudson Executive Capital fully exited Magellan Health Services, Inc. in Q4 2017, selling an estimated $8.52M.
- Hudson Executive Capital's ten largest holdings make up 100% of its $208M portfolio in Q4 2017.
- Hudson Executive Capital opened 2 new positions and closed 1 in Q4 2017.
- Hudson Executive Capital's portfolio value rose 4.8% quarter-over-quarter to $208M.
Based on Hudson Executive Capital's 13F filing for Q4 2017, filed 14 Feb 2018.